A Study of IBI353 (Orismilast) in Chinese Healthy Adults

NCT05490316 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Subjects

Interventions

DRUG: IBI353 (Orismilast)
DRUG: placebo

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.